GlassScriptPhysician profile
Vijay Paudel
NPI 1972596484
$1,304.48
in general payments reported to CMS, 2019-2025
23 companies · $219 in 2025
The $219 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $133 · 2020: $208 · 2021: $29.70 · 2022: $76.33 · 2023: $333 · 2024: $305 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $836 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $836.05 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Asd Specialty Healthcare, LLC | $208.23 | 2020 | |
| Spectrum Pharmaceuticals INC. | $165.72 | 2023 | Rolvedon |
| Gilead Sciences, INC. | $119.54 | 2021-2025 | Trodelvy |
| Biocompatibles, INC. | $114.24 | 2019 | |
| Novartis Pharmaceuticals Corporation | $112.06 | 2023-2025 | |
| Pfizer INC. | $88.62 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $82.76 | 2022-2024 | Zepzelca |
| Abbvie INC. | $52.82 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.21 | 2024 | Gilotrif |
| Celgene Corporation | $43.82 | 2023-2024 | Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $35.98 | 2024-2025 | Opdivo, Krazati |
| Deciphera Pharmaceuticals INC. | $28.08 | 2024 | Qinlock |
| Janssen Biotech, INC. | $26.12 | 2025 | Darzalex, Tecvayli |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Tempus Ai, INC | $20.90 | 2024 | Xt Cdx |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| G1 Therapeutics, INC. | $20.84 | 2022 | |
| Incyte Corporation | $20.45 | 2022 | |
| Merck Sharp & Dohme LLC | $18.93 | 2019 | |
| Aveo Pharmaceuticals, INC. | $17.78 | 2021 | |
| Array Biopharma INC | $16.31 | 2024 | Lorbrena |
| Takeda Pharmaceuticals U.S.A., INC. | $15.96 | 2024 | |
| Springworks Therapeutics, INC. | $15.79 | 2024 | Ogsiveo |
| Kite Pharma, INC. | $14.32 | 2023 | Yescarta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vijay Paudel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.